TrauTec has also revealed that it was participating in the development of industry standards for the category of “recombinant humanized collagen” for medical devices.
On January 6, TrauTec announced that its recombinant Type XVII collagen, which is independently developed and produced by TrauTec, had successfully obtained the INCI name and was included in the existing international cosmetic ingredients catalog, marking TrauTec’s first recombinant collagen material to the international market.
In August 2022, TrauTec received financing of nearly 100 million yuan (about $14.8 million) from Shiseido, the first investment fund of Shiseido China, Ziyue Fund.
The INCI name is an internationally recognized unified and systematic name for identifying cosmetic ingredients. In the U.S. and many countries around the world, regulations require that cosmetic ingredients be labeled using the INCI name. There are more than 16,000 ingredients in the INCI list, the most comprehensive list of ingredients used in cosmetics and personal care products.
It is reported that type XVII collagen, as a transmembrane protein that constitutes a half-bridge particle, mediates the interaction of stem cells with surrounding cells and the extracellular matrix, and maintains the stability of stem cells in hair follicles and skin to maintain the physiological state of hair follicles and skin (hair growth, skin metabolism). TrauTec has been focusing on the research and development of biosynthesis-based recombinant type XVII collagen. It achieved a breakthrough in the development and industrialization of this special type of collagen material from “0 to 1” in the world, and has produced 100% humanized recombinant type XVII collagen with high purity.
In addition, its “30-ton stable fermentation and purification technology” has solved the pain point that recombinant type XVII collagen cannot be produced on a large scale and has become a leading company in the industrialization of recombinant type XVII collagen. In August 2022, the product “Recombinant Type XVII Humanized Collagen” from TrauTec passed the new product appraisal of Jiangsu Provincial Department of Industry and Information Technology, and its overall performance was considered to be internationally advanced and domestically leading.
In the next step, TrauTec will continue to make progress and breakthroughs in technological innovation and independent research and development to further increase the market share of its products.
Cao Kaijie, the sales director of TrauTec, revealed to CHAILEEDO that TrauTec was participating in the development of industry standards for the category of “recombinant humanized collagen” for medical devices, which may have an impact on the application of related products in the medical device industry after the standards are introduced.